Successful maintenance treatment of disseminated nocardiosis with cerebral abscess in a severely immunocompromised patient allergic to trimethoprim-sulfamethoxazole using moxifloxacin and high-dose minocycline: A case report. 2024

Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
Department of Infectious Diseases, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. Electronic address: a.o.hiroshi49@gmail.com.

Nocardiosis in patients after allogeneic hematopoietic stem cell transplantation (HSCT) is rare, but is associated with a significant mortality risk. Although trimethoprim-sulfamethoxazole (TMP/SMX) remains the cornerstone of nocardiosis treatment, optimal alternative therapies for patients intolerant to TMP/SMX are not well-established. Herein, we report a case of disseminated nocardiosis with bacteremia and multiple lesions in the lungs and brain caused by Nocardia farcinica, in a 60-year-old man who had previously undergone allogeneic HSCT and was receiving immunosuppressants for severe chronic graft-versus-host disease. The patient received atovaquone for the prophylaxis of Pneumocystis pneumonia because of a previous serious allergic reaction to TMP/SMX. The patient was initially treated with imipenem/cilastatin and amikacin, which were later switched to ceftriaxone and amikacin based on the results of antimicrobial susceptibility testing. After switching to oral levofloxacin and a standard dose of minocycline, the patient experienced a single recurrence of brain abscesses. However, after switching to oral moxifloxacin and high-dose minocycline, the patient did not experience any relapses during the subsequent two years and seven months of treatment. In treating nocardiosis with brain abscesses, it is crucial to select oral antibiotics based on the antimicrobial susceptibility test results and pharmacokinetics, especially when TMP/SMX is contraindicated. A combination of oral moxifloxacin and high-dose minocycline could be a promising alternative therapy.

UI MeSH Term Description Entries

Related Publications

Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
August 1986, Antimicrobial agents and chemotherapy,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
December 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
April 1991, Journal of the Formosan Medical Association = Taiwan yi zhi,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
May 2022, Annals of clinical microbiology and antimicrobials,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
July 2011, Journal of medical microbiology,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
January 1979, Rocky Mountain medical journal,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
September 2018, BMC ophthalmology,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
January 2024, Transplantation proceedings,
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
December 1996, Presse medicale (Paris, France : 1983),
Hiroshi Yamamoto, and Hirokazu Kuroda, and Nobuhiro Hiramoto, and Toshikazu Hasuike, and Asako Doi, and Hiroaki Nishioka
December 2010, Hinyokika kiyo. Acta urologica Japonica,
Copied contents to your clipboard!